Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Stacks of pills and coins While other drug pricing reform proposals have been voiced, it remains to be seen whether any plan will materialize in time to be used as a campaign tool for the 2020 election. (Photo: Shutterstock)

A one-two punch has put the drug pricing agenda from the White House down for the count. A judge has blocked one rule that would have forced drug companies to disclose prices in TV ads, and a proposal that would have eliminated drug rebates was abandoned after an outcry that it would have raised seniors’ Medicare premiums and cost Medicare millions more for prescription drugs.

Marlene Satter

Marlene Y. Satter has worked in and written about the financial industry for decades.

More from this author


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.